n-((1-allyl-2-pyrrolidinyl)methyl)-5-(3-fluoropropyl)-2-3-dimethoxybenzamide and Learning-Disabilities

n-((1-allyl-2-pyrrolidinyl)methyl)-5-(3-fluoropropyl)-2-3-dimethoxybenzamide has been researched along with Learning-Disabilities* in 1 studies

Other Studies

1 other study(ies) available for n-((1-allyl-2-pyrrolidinyl)methyl)-5-(3-fluoropropyl)-2-3-dimethoxybenzamide and Learning-Disabilities

ArticleYear
Striatal dopamine release and impaired reinforcement learning in adults with 22q11.2 deletion syndrome.
    European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2018, Volume: 28, Issue:6

    22q11.2 deletion syndrome (22q11DS) is a genetic disorder caused by a microdeletion on chromosome 22q11.2 and associated with an increased risk for developing psychosis. The catechol-O-methyltransferase (COMT) gene is located in the deleted region and involved in dopamine (DA) breakdown. Impaired reinforcement learning (RL) is a recurrent feature in psychosis and thought to be related to abnormal striatal DA function. This study aims to examine RL and the potential association with striatal DA-ergic neuromodulation in 22q11DS. Twelve non-psychotic adults with 22q11DS and 16 healthy controls (HC) were included. A dopamine D

    Topics: Adult; Benzamides; Brain Mapping; Catechol O-Methyltransferase; Corpus Striatum; DiGeorge Syndrome; Dopamine; Dopamine D2 Receptor Antagonists; Female; Fluorodeoxyglucose F18; Humans; Intelligence Tests; Learning Disabilities; Magnetic Resonance Imaging; Male; Methionine; Middle Aged; Mutation; Positron-Emission Tomography; Reinforcement, Psychology; Task Performance and Analysis; Valine

2018